Alto Neuroscience, Inc. Fair Value Adjustment of Warrants
Alto Neuroscience, Inc. (ANRO) reported Fair Value Adjustment of Warrants of $130.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-12
- Alto Neuroscience, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was $130.00K, a 113.11% increase year-over-year.
- Alto Neuroscience, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was $115.00K, a 180.49% increase year-over-year.
- Alto Neuroscience, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was $113.00K, a 1783.33% increase year-over-year.
- Alto Neuroscience, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $112.00K, a 133.33% increase year-over-year.
- Alto Neuroscience, Inc. fair value adjustment of warrants for fiscal 2025 was $327.00K, a 10.10% increase from fiscal 2024.
- Alto Neuroscience, Inc. fair value adjustment of warrants for fiscal 2024 was $297.00K.
- Alto Neuroscience, Inc. fair value adjustment of warrants for fiscal 2023 was -$525.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 9 month as first filed | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $130.00K 10-Q · filed 2026-08-12 | $245.00K 10-Q · filed 2026-08-12 | $358.00K derived: sum of 3 quarters · filed 2026-08-12 | $470.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $115.00K 10-Q · filed 2026-05-13 | $228.00K derived: sum of 2 quarters · filed 2026-05-13 | $340.00K derived: sum of 3 quarters · filed 2026-05-13 | $401.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $225.00K derived: sum of 2 quarters · filed 2026-03-16 | $286.00K derived: sum of 3 quarters · filed 2026-08-12 | $327.00K 10-K · filed 2026-03-16 | ||
| 2025-09-30 | $112.00K 10-Q · filed 2025-11-12 | $173.00K derived: sum of 2 quarters · filed 2026-08-12 | $214.00K 10-Q · filed 2025-11-12 | $220.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $61.00K 10-Q · filed 2026-08-12 | $102.00K 10-Q · filed 2026-08-12 | $108.00K derived: sum of 3 quarters · filed 2026-08-12 | $156.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $41.00K 10-Q · filed 2026-05-13 | $47.00K derived: sum of 2 quarters · filed 2026-05-13 | $95.00K derived: sum of 3 quarters · filed 2026-05-13 | $95.00K derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $54.00K derived: sum of 2 quarters · filed 2026-03-16 | $54.00K derived: sum of 3 quarters · filed 2026-03-16 | $297.00K 10-K · filed 2026-03-16 | ||
| 2024-09-30 | $48.00K 10-Q · filed 2025-11-12 | $0.00 10-Q · filed 2024-11-12 | $48.00K derived: sum of 2 quarters · filed 2025-11-12 | $291.00K 10-Q · filed 2025-11-12 | $243.00K 10-Q · filed 2024-11-12 | $125.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $243.00K 10-Q · filed 2025-08-13 | $77.00K derived: sum of 3 quarters · filed 2025-08-13 | -$149.00K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $243.00K 10-Q · filed 2025-05-14 | $77.00K derived: sum of 2 quarters · filed 2025-05-14 | -$149.00K derived: sum of 3 quarters · filed 2025-05-14 | -$271.00K derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$392.00K derived: sum of 2 quarters · filed 2025-03-20 | -$514.00K derived: sum of 3 quarters · filed 2025-03-20 | -$525.00K 10-K · filed 2025-03-20 | ||
| 2023-09-30 | -$226.00K 10-Q · filed 2024-11-12 | -$348.00K derived: sum of 2 quarters · filed 2024-11-12 | -$359.00K 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$122.00K 10-Q · filed 2024-08-13 | -$133.00K 10-Q · filed 2024-08-13 | ||||
| 2023-03-31 | -$11.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |